Serum leptin and its relation to anthropometric measures of obesity in pre-diabetic Saudis

Nasser M Al-Daghri*,1, Omar S Al-Attas2, Khalid Al-Rubeaan3, Mehad Mohieldin4, Mohammad Al-Katari5, Alan F Jones6 and Sudhesh Kumar7

Address: 1Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia, 2Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia, 3Medicine Department, College of Medicine, King Saud University, Riyadh, Saudi Arabia, 4Diabetic Center, KAUH, Riyadh, Saudi Arabia, 5Diabetic Center, KAUH, Riyadh, Saudi Arabia, 6Clinical Biochemistry, Birmingham Heartlands Hospital, Birmingham, B9 5SS, UK and 7Warwick Medical School, Diabetes & Metabolism Unit, University of Warwick, Coventry, CV4 7AL, UK

Email: Nasser M Al-Daghri* - aldaghri2000@hotmail.com; Omar S Al-Attas - omrattas@ksu.edu.sa; Khalid Al-Rubeaan - krubeaan@ksu.edu.sa; Mehad Mohieldin - mohieldin@ksu.edu.sa; Mohammad Al-Katari - malkatari@ksu.edu.sa; Alan F Jones - afjones@doctors.org.uk; Sudhesh Kumar - Sudhesh.Kumar@warwick.ac.uk

* Corresponding author

Abstract

Background: Little information is available on leptin concentrations in individuals with IGT. This study aims to determine and correlate leptin levels to anthropometric measures of obesity in pre-diabetic, (IFG and IGT), type 2 diabetic and normoglycaemic Saudis.

Methods: 308 adult Saudis (healthy controls n = 80; pre-diabetes n = 86; Type 2 diabetes n = 142) participated. Anthropometric parameters were measured and fasting blood samples taken. Serum insulin was analysed, using a solid phase enzyme amplified sensitivity immunoassay and also leptin concentrations, using radio-immunoassay. The remaining blood parameters were determined using standard laboratory procedures.

Results: Leptin levels of diabetic and pre-diabetic men were higher than in normoglycaemic men (12.4 [3.2–72] vs 3.9 [0.8–20.0] ng/mL, (median [interquartile range], p = 0.0001). In females, leptin levels were significantly higher in pre-diabetic subjects (14.09 [2.8–44.4] ng/mL) than in normoglycaemic subjects (10.2 [0.25–34.8] ng/mL) (p = 0.046). After adjustment for BMI and gender, hip circumference was associated with log leptin (p = 0.006 with R2 = 0.086) among all subjects.

Conclusion: Leptin is associated with measures of adiposity, hip circumference in particular, in the non-diabetic state among Saudi subjects. The higher leptin level among diabetics and pre-diabetics is not related to differences in anthropometric measures of obesity.

Background

Saudi Arabia, a Middle Eastern country with a population of 22 million, has undergone significant economic and cultural changes over the past thirty years. Approximately 60% of the population are urbanised and have adopted a ‘Westernised’ lifestyle in terms of diet and physical activity.
and not leptin deficiency proportional to body fat mass, but it is leptin resistance In human beings, serum leptin concentration is directly proportional to body fat mass, indicating other possible factors for its determination [21,22]. Leptin may be a marker of risk of CHD, at least in males, and contributes to the CHD risk profile in subjects with insulin resistance [23]. Not much information is available on leptin concentrations in individuals with IGT and to our knowledge there has been no study of leptin in pre-diabetics within the region.

This study aims to determine and compare the serum leptin concentrations of diabetic and non-diabetic patients with those in patients who have pre-diabetes and to correlate it with anthropometric measures of obesity.

**Methods**

**Subjects**

In the present study, subjects were selected from the roster of adult, ambulant, non-pregnant patients attending the Diabetes Center at the King Abdulaziz University Hospital in Riyadh, Saudi Arabia. Ethical approval was obtained from the local institution’s review committee and consent was obtained from all participants. For the purposes of this study, subjects were classified into categories of abnormal glucose homeostasis if they had a single abnormal FPG. 142 patients had type-2 diabetes (FPG > 7.1 mmol/L) (97 males and 45 females). All patients with diabetes were treated with a low-carbohydrate diet, with or without oral antidiabetic agents, mainly glibenclamide and metformin. 86 pre-diabetic subjects (49 males and 37 females) were defined on the basis of modified ADA criteria [24]. Pre-diabetes was diagnosed when the fasting plasma glucose was between 5.6 mmol/L – 7.0 mmol/L (100–126 mg/dL). 80 Saudi individuals (45 males and 35 females), with no prior history of CHD or diabetes, were recruited as controls (no diabetes).

**Anthropometric parameters**

All subjects underwent a full physical examination and completed a general questionnaire. Height was measured to the nearest 0.5 cm and weight to the nearest 0.1 kg. Waist circumference (cm) was measured at the horizontal circumference midway between the lowest rib margin and the iliac crest and the hip circumference (cm) was measured at the maximum circumference over the buttocks. Body mass index (BMI) was calculated as weight (kg) divided by height (m) squared. Groups were matched for BMI.

**Laboratory methods**

Blood samples were collected after a 12-hour fast for the determination of glucose, insulin, total cholesterol, HDL, triglycerides, apolipoprotein A1 (apo A1), apolipoprotein A2 (apo A2) and leptin. All samples were stored at -70°C prior to analysis by using routine laboratory methods, except for insulin and leptin assay. Insulin was analyzed by a solid phase enzyme amplified sensitivity immunoassay (Medgenix INS-ELISA, Biosource, Belgium). Leptin concentrations were measured by radio-immunoassay (Linco Research, St. Charles, MO). Homeostasis model assessment-insulin resistance (HOMA-IR) and β-cell function index were derived using the HOMA equation [25].

**Statistical Analysis**

Data were analysed using the Statistical Package for the Social Sciences (SPSS) version 10 (SPSS, Evanston, IL, USA) for Windows. Biochemical parameters not normally
distributed were analyzed after being logarithmically transformed. Students' unpaired t-test and one-way analysis of variance (ANOVA) were used to compare the results of the different groups. Simple and partial correlation coefficients between the variables were determined and multiple regression analysis was performed to determine the relationships between the variables of interest. Data were expressed as mean (SD) or median (range); statistical significance was set at p < 0.05.

Results
Table 1 presents the clinical and metabolic characteristics of the male subjects. It is evident that those in the diabetes group were significantly older (p < 0.0001), with higher fasting glucose and leptin levels (p < 0.0001, 0.012 respectively) than those in the pre-diabetes and control groups. At the same time, the pre-diabetes group had significantly elevated systolic blood pressure (p = 0.046) and fasting glucose levels (p < 0.0001), compared to the controls.

Table 2 highlights the clinical and metabolic parameters in the females. In the diabetes and pre-diabetes group, FPG and LDL were significantly higher than in the control. Total cholesterol was also significantly higher in women with diabetes (p = 0.03).

Serum leptin was significantly higher in the men with diabetes than in their non-diabetic counterparts [12.4 [3.2–72]; p = 0.0001]. In the female patients, serum leptin was higher in those with pre-diabetes (14.09 [2.8–44.4]) than in the controls.

Stepwise linear regression analysis revealed a positive correlation between log leptin and hip circumference and BMI (R = 0.31, p = 0.002; R = 0.26, p = 0.006 respectively). Even after adjustment for BMI, there was a positive association between log leptin and hip circumference with an R² = 0.086 and p value of 0.006 (see Figure 1). The rest of the findings were non-contributory.

Discussion
Insulin resistance is the common factor in a range of risk factors for atherosclerosis, specifically hypertension, dyslipidemia and abnormal glucose metabolism. As has been shown in other populations [26-29], the pre-diabetic males had a significantly higher systolic blood pressure and fasting plasma glucose than the control subjects had. Many [30,31], but not all studies [32,33] of the general population have shown a positive association of indices of insulin resistance with arterial wall changes, CHD and CVD. The clustering of risk factors increases the risk of atherosclerosis [34-36].

Data were presented according to gender, since it is already an established fact that leptin levels are significantly higher in women than in men. There are several possible explanations for the difference. One is that females have more adipose tissue than males, but a growing literature indicates that estrogen, especially at higher levels, will stimulate the production of leptin, whereas androgens will suppress the levels of leptin [37]. In this cross-sectional study, we found positive correlations between leptin and hip circumference in pre-diabetic patients. This is consistent with a previous study, which also showed that this group is at high risk of developing

| Table 1: Clinical characteristics and metabolic parameters of male subjects with type-2 diabetes, pre-diabetes and no diabetes |
|---------------------|---------------------|---------------------|
|                      | No Diabetes (N=45)  | Pre-diabetes (N=49) | Type-2 Diabetes (N=97) |
| Age (years)          | 45.7(12.6)          | 50.1(11.6)          | 54.5(10.7)*             |
| Systolic blood pressure (mm Hg) | 123.1(16.9) | 132.8(25.1)* | 130.7(17.5)             |
| Diastolic blood pressure (mm Hg) | 79.9(9.1) | 85.1(11.4) | 82.9(10.5)             |
| BMI (Kg/m²)          | 29.2(7.3)           | 28.5(4.3)           | 27.3(4.1)               |
| Waist (cm)           | 93.7(18.2)          | 98.6(10.1)          | 96.4(15.1)              |
| Hips (cm)            | 95.9(15.7)          | 100.5(13.9)         | 99.8(14.4)              |
| Fasting Glucose (mmol/L) | 4.8(0.6) | 6.1(0.4)* | 13.7(5.0)*             |
| Cholesterol (mmol/L) | 5.2(1.6)           | 5.6(1.4)            | 6.5(1.9)*               |
| LDL (mmol/L)         | 0.94(0.3)           | 1.2(0.4)            | 0.9(0.4)                |
| Triglyceride (mmol/L)| 1.8(0.6–6.7)       | 1.9(0.7–6.3)        | 2.5(1.6–15)             |
| VLDL (mmol/L)        | 3.3(1.1)            | 3.9(1.6)            | 4.2(1.8)*               |
| Insulin µmol/L       | 12.6(2–99)          | 12.3 (2–36)         | 16.2(2–70)              |
| Leptin ng/mL         | 3.9(0.8–20)         | 7.6(1.2–72)*        | 12.4(3.2–72)*            |
| APO A1 mg/dL         | 0.9(0.3)            | 0.9(0.5)            | 0.9(0.3)                |
| APO A2 mg/dL         | 0.4(0.1)            | 0.4(0.1)            | 0.3(0.1)                |
| HOMA-IR              | 3.3(0.3–23.8)       | 3.5(0.5–10.2)       | 9.6(1.1–49.7)*          |

Data are presented as means (SD) or as medians (interquartile range) for insulin, leptin and HOMA-IR data. The P-values shown are comparisons of metabolic characteristics for case control versus either prediabetic patients or those with T2DM: a) p = 0.046; b) p = 0.03; c) p = 0.012; d) p = 0.004; e) p = 0.001; f) p < 0.0001.
CHD [38]. The positive association with hip circumference remained significant after adjusting for gender and BMI, which confirmed the results in previous studies for healthy men and women [39,40]. With impaired glucose tolerance, small changes in circulating insulin also alter insulin levels [41].

Serum leptin concentration may contribute to the risk of CVD by altering lipid metabolism and contributing to hypertension via the activation of the sympathetic nervous system and increasing renal sodium re-absorption [42,43]. However, in our study there was no correlation between leptin and blood pressure. In another study, leptin signaling directly promoted atherosclerosis and may therefore represent a therapeutic target for the prevention of atherosclerosis [44]. Lichnovska and her colleagues in their recent report mentioned the significant role of serum leptin in the progression of insulin resistance, but this was not confirmed in the present study [45]. The difference can be due to the fact that the earlier study considered elderly and hyperlipemic patients, while the present study focused on pre-diabetic, diabetic and non-diabetic adults. Our results, however, confirm the results of Adamia et al., which reveal no correlation between leptin and insulin resistance [46].

A family history of diabetes was found to have a negative association with leptin in pre-diabetic patients; this confirms a previous study which reported that healthy lean non-diabetic Asian Indians are more insulin resistant than other ethnic groups, despite similarities in their living environment [47]. Waist circumference has been postulated to have closer associations with the biomarkers of CHD than BMI has [48]. The association of leptin to waist circumference (a surrogate for upper body obesity) and hip circumference confirms findings in Mexican American populations [49,50]. After adjustment for BMI, serum leptin concentrations in pre-diabetic men were independent of waist circumference, but in women they were associated with hip circumference. Hip circumference is a proxy measure of peripheral fat in serum leptin concentrations, aside from the fact that women have a significantly larger volume of subcutaneous fat than do men. In the control subjects, leptin concentrations were directly and significantly related to subcutaneous fat, with a strong inverse relationship to waist-hip ratio. When the results were considered according to gender, it was found that 33.1% of the male Saudis with waist circumference >102 cm, had diabetes. In female subjects, 27% of those with a high waist circumference ≥88 cm had diabetes, compared to only 13.4% of those with a normal waist circumference [20]. Leptin is related to waist and hip circumference and is directly proportional to body fat. However, in those with diabetes, this relationship is lost, reflecting the effect of other factors, including hyperinsulinaemia and the activation of sub-clinical inflammation.

**Conclusion**

The significant correlation of leptin to selected anthropometric measurements of obesity is confirmed in non-diabetic Saudi Subjects. In those with diabetes, this relationship is lost, reflecting the effect of other factors, including hyperinsulinaemia and the activation of sub-clinical inflammation.
Figure 1
Log leptin (ng/ml) vs. Hip circumference (cm). The correlation of log leptin (ng/mL) with hip circumference (cm) using univariate analysis across all Saudi subjects, case controls, T2DM and pre-diabetic subjects. Blue denotes the actual values with the line of best fit shown in square (R² 0.086 p-value = 0.006).

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
NA for the concept and design as well as statistical analysis; OA for the drafting and revising of the manuscript; KA and AJ for the acquisition and interpretation of data; MM and MK for the screening and collection of data; KS for the concept and final revision of the manuscript. All the authors have read and approved the final version.

Acknowledgements
The authors extend their sincerest appreciation to Dr. Shaun Louie Sabico for his writing and editing assistance.

References
1. al-Nuaim AR, al-Rubeaan K, al-Mazrou Y, al-Attas O, al-Daghari N, Khaja T: High prevalence of overweight and obesity in Saudi Arabia. Int J Obes Relat Metab Disord 1996, 20(11):547-552.
2. al-Nuaim AR, al-Rubeaan K, al-Mazrou Y, al-Attas O, al-Daghari N: Prevalence of hypercholesterolemia in Saudi Arabia, epidemiological study. Int J Cardiol 1996, 54(1):41-49.
3. al-Shammarri SA, Ali M, al-Shammarri A, al-Maatouq M, Tannier A, Armstrong K: Blood lipid concentrations and other cardiovascular risk factors among Saudis. Fam Pract 1994, 11(2):153-158.
4. Al-Dawood KM: Pattern of smoking among parents of schoolboys. Saudi Med J 2000, 21(8):735-739.
5. Al-Nozha MM, Arafah MR, Al-Mazrou YY, Al-Harith SS, Arafah MK, Khalil MZ, Stahl MH, Al-Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobireek A: Diabetes mellitus in Saudi Arabia. Saudi Med J 2004, 25(11):1603-1610.
6. Al-Nuaim AR, al-Rubeaan K, Bartlett WA, al-Attas O, Jones AF, Kumar S: Impaired fasting glucose concentrations in non-diabetic patients with ischemic heart disease: a marker for a worse prognosis. Am Heart J 2001, 141(3):485-490.
7. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, Al-Harith SS, Arafah MK, Khalil MZ, Al-Khadaa A, Al-Marzouki K, Nouh MS, Abdullah M, Attas O, Al-Shahid MS, Al-Mobireek A: Diabetes mellitus in Saudi Arabia. Saudi Med J 2004, 25(11):1603-1610.
8. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27(Suppl 1):S5-S10.
9. Lowe LP, Liu K, Greenland P, Metzger BE, Dyer AR, Stanler J: Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study. Diabetes Care 1997, 20(2):163-169.
10. Jackson CA, Yudkin JS, Forrest RD: A comparison of the relationships of the glucose tolerance test and the glycaed haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. Diabetes Care 1997, 20(7):183-187.
11. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R, Baltimore Longitudinal Study of Aging: The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal study of aging. Diabetes Care 2003, 26(2):360-366.
12. Kannel WB, McGee DL: Diabetes and cardiovascular disease: The Framingham Study. JAMA 1979, 241(19):2035-2038.
13. Gu K, Cowie CC, Harris MI: Mortality in adults with and without diabetes in a national cohort of the US population, 1971-1991. Diabetes Care 1998, 21(7):1326-1331.
14. Woodward M, Zhang X, Barzil J, Pan W, Ueshima H, Rodgers A, MacMahon S, Asia Pacific Cohort Studies Collaboration: The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care 2003, 26(2):360-366.
15. Kannel WB: Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985, 110(5):1100-1107.
16. Stamler J, Vaccaro O, Nestow JD, Wentworth D: Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16(2):434-444.
17. Barzilay J, Spiekerman CF, Kuller LH, Burke GL, Bittner V, Gottdiener JS, Brancati FL, Orchard TJ, O’Leary DH, Savage PJ: Cardiovascular Health Study: Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: the Cardiovascular Health Study. Diabetes Care 2001, 24(7):1233-1239.
18. Fisman EZ, Motro M, Tenenbaum A, Boyko E, Mandelzweig L, Behar MA, Boyko V, Mandelzweig L: Impaired glucose tolerance as a disease. Am J Cardiol 1999, 83(13):1475-1484.
19. Mahon S, Asia Pacific Cohort Studies Collaboration: Impact of impaired fasting glucose on cardiovascular events from normal glucose tolerance to type 2 diabetes in the Framingham Study. JAMA 1993, 269(15):1100-1107.
20. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27(Suppl 1):S5-S10.
21. Matthews DR, Rudenski AS, Naylor BA, Treacher DF, Turner RC: The natural history of progression from normal glucose tolerance to type 2 diabetes in the Framingham Study: Insights from the Framingham Study. JAMA 1993, 270(17):1410-1415.
tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990, 131(3):443-453.

29. Weyer C, Bogardus C, Holst DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999, 104(6):787-794.

30. Pyorala M, Miettinen H, Laasko M, Pyorala K: Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Stroke 1998, 29(9):1860-1866.

31. Jarrett RJ: Why is insulin not a risk factor for coronary heart disease? Diabetes 1994, 37(9):947-947.

32. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M: Carotid artery intima-media thickness in elderly patients with NIDDM and in nondiabetic subjects. Stroke 1996, 27(11):1896-1992.

33. Welin L, Eriksson H, Larsson B, Ohlson LO, Svardsudd K, Tibblin G: Hyperinsulinaemia is not a major coronary risk factor in elderly men: The study of men born in 1913. Diabetologia 1992, 35(6):766-770.

34. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes 1991, 40(3):173-194.

35. Reaven GM, Laws A: Insulin resistance, compensatory hyperinsulinaemia, and coronary heart disease. Diabetologia 1994, 37(9):948-952.

36. Fujioka S, Matsuzawa Y, Tokunaga K, Tarui S: Contribution of intra-abdominal fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism 1987, 36(1):54-59.

37. Castracane VD, Henson MC: When did leptin become a reproductive hormone? Semin Reprod Med 2002, 20(2):89-92.

38. Alexander CM, Landsman PB, Teutsch SM: Diabetes mellitus, impaired fasting glucose, atherothrombotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 2000, 86(9):979-992.

39. Zhong N, Wu XP, Xu ZR, Wang AH, Luo XH, Cao XZ, Xie H, Shan PF, Liao EY: Relationship of serum leptin with age, body weight, body mass index, and bone mineral density in healthy mainland Chinese women. Clin Chim Acta 2005, 351(1-2):161-168.

40. Maugeri D, Bonanno MR, Speciale S, Santangelo A, Lentini A, Russo MS, Calanna A, Malaguarnera M, Motta M, Testai M, Panebianco P: The leptin, a new hormone of adipose tissue: clinical findings and perspectives in geriatrics. Arch Gerontol Geriatr 2002, 34(1):47-54.

41. Leonhardt W, Horn R, Brabant G, Breidert M, Temelkova-Kurtschien T, Fucker K, Hanefeld M: Relation of free and specifically bound leptin to insulin secretion in patients with impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes 1997, 107(1):46-52.

42. Asakawa H, Tokunaga K, Kawakami F: Relationship of leptin level with metabolic disorders and hypertension in Japanese type 2 diabetes mellitus patients. J Diabetes Complications 2001, 15(2):57-62.

43. Couillard C, Mirriouge P, Prud'homme D, Nadeau A, Tremblay A, Bouchard C, Despres JP: Plasma leptin concentrations: gender differences and associations with metabolic risk factors for cardiovascular disease. Diabetologia 1997, 40(10):1178-1184.

44. Reilly MP, Iqbal N, Schutz M, Wolfe ML, Scally M, Localio AR, Rader DJ, Kimmel SE: Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab 2004, 89(8):3872-3878.

45. Lichnovska R, Gwozdzie wiczowa A, Hrebicek J: Gender differences in factors influencing insulin resistance in elderly hyperlipidaemic non-diabetic subjects. Cardiovasc Diabetol 2002, 1:4.

46. Adamiya N, Virsaladze D, Charkviani N, Skhirtladze M, Khutsishvili M: Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant premenopausal females with type 2 diabetes. Georgian Med News 2007:52-55.

47. Liew CF, Seah ES, Yeo KP, Lee KO, Wise SD: Lean, nondiabetic Asian Indians have decreased insulin sensitivity and insulin clearance, and raised leptin compared to Caucasians and Chinese subjects. Int J Obes Relat Metab Disord 2003, 27(7):784-789.